GlassScriptPhysician profile
Hetal B Naik
NPI 1619210101
$1,966.66
in general payments reported to CMS, 2019-2025
11 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $36.89 · 2023: $71.43 · 2024: $224 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,051 · Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,051.19 |
| Food and Beverage | $658.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,476.39 | 2021-2025 | Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System, Atriclip Laa Exclusion System |
| Edwards Lifesciences Corporation | $170.81 | 2023-2024 | Sapien 3 Ultra Resilia, Inspiris Resilia Aortic Valve |
| Kci USA, INC. | $106.30 | 2021 | |
| Smith+Nephew, INC. | $48.71 | 2024 | Pico 14, Renasys Touch |
| Abiomed | $36.89 | 2022 | |
| La Jolla Pharmaceutical Company | $34.70 | 2024-2025 | Giapreza |
| Cardiva Medical, INC. | $24.20 | 2025 | Cardiva Vascade 6/7f Vcs |
| Pfizer INC. | $20.78 | 2023 | |
| Haemonetics Corporation | $17.14 | 2025 | Teg6s Hemostasis System |
| Janssen Pharmaceuticals, INC | $16.28 | 2023 | Xarelto |
| Amgen INC. | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetal Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.